Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | john.elicker@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 23300 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
Company recently showed positive data in cancer and graft versus host disease.
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).
CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Highlights for the week that ESMO 2018 began. Oncology news had important implications for investors across the space
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Lead candidate targeting graft-versus-host disease (GvHD) (Image: Equillium).
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | john.elicker@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 23300 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
Company recently showed positive data in cancer and graft versus host disease.
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).
CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Highlights for the week that ESMO 2018 began. Oncology news had important implications for investors across the space
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Lead candidate targeting graft-versus-host disease (GvHD) (Image: Equillium).
| Last Price 63.94 | Change $ 1.53 | Change % 2.45 | Tick N/A |
| Bid 64.02 | Bid Size 100.00 | Ask 64.39 | Ask Size 100.00 |
| Open 62.42 | High 64.22 | Low 62.42 | Prev Close 62.41 |
| Last Trade | Volume 17.4 mi | 52 Wk Hi 64.22 | 52 Wk Low 42.48 |
| Market Cap 149.9 bi | Ex-Div Date | Div Rate 1.80 | Yield 2.8150 |
| Shares 2,344,194,343.00 | EPS (TTM) 3.45 | PE Ratio 18.10 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 9 | 156 |
| Number of Buys | 5 | 95 |
| Number of Sells | 4 | 61 |
| Net Activity | 14249 | 331983 |
| Last 10 Buys | Shares |
|---|---|
| Dinesh C. Paliwal | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| James M. Cornelius | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Thomas J. Lynch | 1,000 |
| Sandra Leung | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Louis S. Schmukler | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Louis S. Schmukler | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 72 | 72 | 72 | 72 |
| Low Target Price Estimate | 47 | 47 | 47 | 47 |
| Mean Target Price Estimate | 60.55 | 60.91 | 60.91 | 60.55 |
| Standard Deviation | 7.88 | 8.19 | 8.19 | 7.88 |
| Date of Most Recent Estimate | 06/05/18 | 05/23/18 | 05/14/18 | 06/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2018-04-26 |
| 8-K | Report of unscheduled material events or corporate changes. | 27 | 2018-04-26 |
| DEFA14A | Additional proxy soliciting materials - definitive | 15 | 2018-04-23 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-05 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 |
| Moderate Buy | 0 | 0 | 1 | 1 |
| Hold | 8 | 7 | 6 | 6 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 |
| Mean Rec. | 2.23 | 2.08 | 2.18 | 2.1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait